Thu, Aug 21, 2014, 1:24 PM EDT - U.S. Markets close in 2 hrs 36 mins

Recent

% | $
Quotes you view appear here for quick access.

MiMedx Group, Inc. Message Board

  • strut1702 strut1702 Oct 1, 2013 1:40 PM Flag

    Motley Fool MDXG

    Come on Sean Williams, you're smarter than this.

    " MiMedx still has an unresolved untitled letter from the Food and Drug Administration to deal with, and until we have better clarity on its ability to continue to manufacture its products with the blessing of the FDA, I'd suggest keeping your distance."

    It's INJECTABLE business only.

    "Conversely, the confirmation of the receipt of an untitled letter solidifies the seriousness of these allegations and poses the potential to put a serious dent in MiMedx's revenue growth."

    How? Injectables is projected at ~15% of revenue.

    Epifix Micronized is physician choice and Amniofix doesn't generate much revenue. Amniofix isn't covered by majority of payers and will require additional studies regardless of how the FDA rules. Injectables won't be a driver of revenue for at least 5-10 years.

    Unless Sean is projecting huge legal fees/settlement

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
MDXG
6.82-0.09(-1.30%)1:15 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.